Jul. 16 at 3:59 PM
$CMND is making progress on its intranasal MEAI development program, reporting positive retention data for its psychedelic-based neuroplastogen candidate.
Clearmind’s formulation showed stronger nasal tissue residence compared with a standard MEAI solution in ex vivo testing, maintaining a higher percentage of the initial adhered dose over a 30-minute evaluation period.
Improving nasal retention is a key challenge for consistent dosing, and these results support the company’s mucoadhesive delivery approach as it advances MEAI for potential Alcohol Use Disorder treatment.
The next important steps will be further validation and clinical progress.
